Estazolam-D5 is a deuterated derivative of estazolam, a benzodiazepine used primarily for its anxiolytic and sedative properties. The "D5" designation indicates that five hydrogen atoms in the molecule have been replaced with deuterium, a stable isotope of hydrogen, which can be useful in pharmacokinetic studies and research applications. Estazolam itself is characterized by its ability to enhance the effects of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, leading to increased inhibitory neurotransmission. This results in its therapeutic effects, including sedation, muscle relaxation, and anxiolysis. The deuterated form may exhibit altered metabolic pathways compared to its non-deuterated counterpart, potentially affecting its pharmacodynamics and pharmacokinetics. Estazolam-D5 is primarily utilized in research settings, particularly in studies involving drug metabolism and the development of analytical methods for detecting benzodiazepines in biological samples. As with other benzodiazepines, caution is advised regarding its use due to the potential for dependence and withdrawal symptoms.

ESTAZOLAM-D5

170082-16-3: 4H-1,2,4Triazolo4,3-a1,4benzodiazepine, 8-chloro-6-(phenyl-d5)-

CAS 170082-16-3: ESTAZOLAM-D5

Estazolam-d5

Ref: TR-E668382

Estazolam-D5 0.1 mg/ml in Methanol

Ref: TR-LGCAMP1354.80-02